nach oben

Current Neurology and Neuroscience Reports

Erschienen in:

01.10.2014 | Neuroimaging (DJ Brooks, Section Editor)

Imaging Frontotemporal Lobar Degeneration

verfasst von: Janine Diehl-Schmid, Oezguer A. Onur, Jens Kuhn, Traugott Gruppe, Alexander Drzezga

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

The term frontotemporal lobar degeneration (FTLD) refers to a group of neurodegenerative disorders that target the frontal and temporal lobes. It accounts for approximately 10 % of pathologically confirmed dementias but has been demonstrated to be as prevalent as Alzheimer’s disease in patients below the age of 65. The 3 major clinical syndromes associated with FTLD include behavioral variant frontotemporal dementia, semantic and nonfluent variants of primary progressive aphasia. The more recently introduced term logopenic variant appears to represent an atypical form of Alzheimer’s disease in the majority of cases. The neuropathology underlying these clinical syndromes is very heterogeneous and does not correlate well with the clinical phenotype. This causes great difficulties in early and reliable diagnosis and treatment of FTLD. However, significant advances have been made in recent years via the application of magnetic resonance imaging and positron emission tomography imaging methods as biomarkers. The current review aims to provide a synopsis on the value of magnetic resonance imaging-based and molecular imaging procedures in FTLD.

Borroni B, Alberici A, Grassi M, et al. Is frontotemporal lobar degeneration a rare disorder? Evidence from a preliminary study in Brescia county. Italy J Alzheimers Dis. 2010;19:111–6.

Onyike CU, Diehl-Schmid J. The epidemiology of frontotemporal dementia. Int Rev Psychiatry. 2013;25:130–7.PubMedCrossRefPubMedCentral

Johnson JK, Diehl J, Mendez MF, et al. Frontotemporal lobar degeneration: demographic characteristics of 353 patients. Arch Neurol. 2005;62:925–30.PubMed

Mackenzie IR, Foti D, Woulfe J, Hurwitz TA. Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions. Brain. 2008;131:1282–93.PubMedCrossRef

Diehl-Schmid J, Pohl C, Ruprecht C, Wagenpfeil S, Foerstl H, Kurz A. The Ekman 60 faces test as a diagnostic instrument in frontotemporal dementia. Arch Clin Neuropsychol. 2007;22:459–64.PubMedCrossRef

Hodges JR, Davies R, Xuereb J, Kril J, Halliday G. Survival in frontotemporal dementia. Neurology. 2003;61:349–54.PubMedCrossRef

Goldman JS, Farmer JM, Wood EM, et al. Comparison of family histories in FTLD subtypes and related tauopathies. Neurology. 2005;65:1817–9.PubMedCrossRef

8.••

Sieben A, Van Langenhove T, Engelborghs S, et al. The genetics and neuropathology of frontotemporal lobar degeneration. Acta Neuropathol. 2012;124:353–72. Important paper on the various genotypes and neuropathologies involved in FTLD.PubMedCrossRefPubMedCentral

Renton AE, Majounie E, Waite A, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257–68.PubMedCrossRefPubMedCentral

10.••

Rademakers R, Neumann M, Mackenzie IR. Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol. 2012;8:423–34. Recent advances corresponding to the molecular and genetic aspects of FTLD are highlighted and their potential relevance with regard to targeted diagnostic tests and therapies is discussed. PubMedPubMedCentral

11.••

Rascovsky K, Hodges JR, Knopman D, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456–77. Important paper on the clinical value of the novel diagnostic criteria for bvFTD.PubMedCrossRefPubMedCentral

12.••

Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76:1006–14. Important paper on the classification of the different variants of PPA (complementary to reference Nr. 11).PubMedCrossRefPubMedCentral

13.

Snowden JS, Bathgate D, Varma A, Blackshaw A, Gibbons ZC, Neary D. Distinct behavioural profiles in frontotemporal dementia and semantic dementia. J Neurol Neurosurg Psychiatry. 2001;70:323–32.PubMedCrossRefPubMedCentral

14.

Bozeat S, Lambon Ralph MA, Patterson K, Garrard P, Hodges JR. Non-verbal semantic impairment in semantic dementia. Neuropsychologia. 2000;38:1207–15.PubMedCrossRef

15.

Marczinski CA, Davidson W, Kertesz A. A longitudinal study of behavior in frontotemporal dementia and primary progressive aphasia. Cogn Behav Neurol. 2004;17:185–90.PubMed

16.

Rabinovici GD, Rascovsky K, Miller BL. Frontotemporal lobar degeneration: clinical and pathologic overview. Handb Clin Neurol. 2008;89:343–64.PubMedCrossRef

17.••

Mesulam MM, Weintraub S, Rogalski EJ, Wieneke C, Geula C, Bigio EH. Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia. Brain. 2014;137:1176–92. Important paper on the heterogeneity of underlying pathologies in FTLD and the difficulty of the clinical diagnosis of the different subtypes (with regard to the pathology involved).PubMedCrossRef

18.

Bonner MF, Ash S, Grossman M. The new classification of primary progressive aphasia into semantic, logopenic, or nonfluent/agrammatic variants. Curr Neurol Neurosci Rep. 2010;10:484–90.PubMedCrossRefPubMedCentral

19.

Mesulam M, Wieneke C, Rogalski E, Cobia D, Thompson C, Weintraub S. Quantitative template for subtyping primary progressive aphasia. Arch Neurol. 2009;66:1545–51.PubMedCrossRefPubMedCentral

20.

Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain. 2007;130:2616–35.PubMedCrossRef

21.

Whitwell JL, Przybelski SA, Weigand SD, et al. Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain. 2009;132:2932–46.PubMedCrossRefPubMedCentral

22.••

Schroeter ML, Laird AR, Chwiesko C, et al. Conceptualizing neuropsychiatric diseases with multimodal data-driven meta-analyses - The case of behavioral variant frontotemporal dementia. Cortex. 2014;57C:22–37. Important Meta-Analysis indicating the core areas of neurodegeneration involved in bvFTD.CrossRef

23.

Schroeter ML, Raczka K, Neumann J, von Cramon DY. Neural networks in frontotemporal dementia–a meta-analysis. Neurobiol Aging. 2008;29:418–26.PubMedCrossRef

24.

Pan PL, Song W, Yang J, et al. Gray matter atrophy in behavioral variant frontotemporal dementia: a meta-analysis of voxel-based morphometry studies. Dement Geriatr Cogn Disord. 2012;33:141–8.PubMedCrossRef

25.

Schroeter ML, Raczka K, Neumann J, Yves von Cramon D. Towards a nosology for frontotemporal lobar degenerations-a meta-analysis involving 267 subjects. Neuroimage. 2007;36:497–510.PubMedCrossRef

26.

Rohrer JD, Clarkson MJ, Kittus R, et al. Rates of hemispheric and lobar atrophy in the language variants of frontotemporal lobar degeneration. J Alzheimers Dis. 2012;30:407–11.PubMed

27.

Lu PH, Mendez MF, Lee GJ, et al. Patterns of brain atrophy in clinical variants of frontotemporal lobar degeneration. Dement Geriatr Cogn Disord. 2013;35:34–50.PubMedCrossRefPubMedCentral

28.

Rohrer JD, Ridgway GR, Modat M, et al. Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations. Neuroimage. 2010;53:1070–6.PubMedCrossRefPubMedCentral

29.••

Whitwell JL, Weigand SD, Boeve BF, et al. Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain. 2012;135:794–806. Important paper on imaging findings in different genotypes involved in FTLD.PubMedCrossRefPubMedCentral

30.

Rohrer JD, Rosen HJ. Neuroimaging in frontotemporal dementia. Int Rev Psychiatry. 2013;25:221–9.PubMedCrossRef

31.

Agosta F, Scola E, Canu E, et al. White matter damage in frontotemporal lobar degeneration spectrum. Cereb Cortex. 2012;22:2705–14.PubMedCrossRef

32.

Zhang Y, Tartaglia MC, Schuff N, et al. MRI signatures of brain macrostructural atrophy and microstructural degradation in frontotemporal lobar degeneration subtypes. J Alzheimers Dis. 2013;33:431–44.PubMedPubMedCentral

33.

Grossman M, Powers J, Ash S, et al. Disruption of large-scale neural networks in non-fluent/agrammatic variant primary progressive aphasia associated with frontotemporal degeneration pathology. Brain Lang. 2013;127:106–20.PubMedCrossRef

34.

Coulthard E, Firbank M, English P, et al. Proton magnetic resonance spectroscopy in frontotemporal dementia. J Neurol. 2006;253:861–8.PubMedCrossRef

35.

Chawla S, Wang S, Moore P, et al. Quantitative proton magnetic resonance spectroscopy detects abnormalities in dorsolateral prefrontal cortex and motor cortex of patients with frontotemporal lobar degeneration. J Neurol. 2010;257:114–21.PubMedCrossRefPubMedCentral

36.

Kantarci K, Petersen RC, Boeve BF, et al. 1H MR spectroscopy in common dementias. Neurology. 2004;63:1393–8.PubMedCrossRefPubMedCentral

37.

Kizu O, Yamada K, Ito H, Nishimura T. Posterior cingulate metabolic changes in frontotemporal lobar degeneration detected by magnetic resonance spectroscopy. Neuroradiology. 2004;46:277–81.PubMedCrossRef

38.

Raichle ME. Behind the scenes of functional brain imaging: a historical and physiological perspective. Proc Natl Acad Sci U S A. 1998;95:765–72.PubMedCrossRefPubMedCentral

39.

Hu WT, Wang Z, Lee VM-Y, Trojanowski JQ, Detre JA, Grossman M. Distinct cerebral perfusion patterns in FTLD and AD. Neurology. 2010;75:881–8.PubMedCrossRefPubMedCentral

40.

Logothetis NK, Pfeuffer J. On the nature of the BOLD fMRI contrast mechanism. Magn Reson Imaging. 2004;22:1517–31.PubMedCrossRef

41.

Rombouts SA, van Swieten JC, Pijnenburg YA, Goekoop R, Barkhof F, Scheltens P. Loss of frontal fMRI activation in early frontotemporal dementia compared to early AD. Neurology. 2003;60:1904–8.PubMedCrossRef

42.

Wilson SM, Dronkers NF, Ogar JM, et al. Neural correlates of syntactic processing in the nonfluent variant of primary progressive aphasia. J Neurosci: Off J Soc Neurosci. 2010;30:16845–54.CrossRef

43.

Wilson SM, Brambati SM, Henry RG, et al. The neural basis of surface dyslexia in semantic dementia. Brain. 2009;132:71–86.PubMedCrossRefPubMedCentral

44.

Biswal B, Yetkin FZ, Haughton VM, Hyde JS. Functional connectivity in the motor cortex of resting human brain using echo-planar MRI. Magn Reson Med. 1995;34:537–41.PubMedCrossRef

45.••

Seeley WW, Crawford RK, Zhou J, Miller BL, Greicius MD. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62:42–52. Groundbreaking paper, illustrating the involvement of different functional connectivity networks in different forms of neurodegenerative disorders.PubMedCrossRefPubMedCentral

46.

Bonnelle V, Ham TE, Leech R, et al. Salience network integrity predicts default mode network function after traumatic brain injury. Proc Natl Acad Sci U S A. 2012;109:4690–5.PubMedCrossRefPubMedCentral

47.••

Zhou J, Greicius MD, Gennatas ED, et al. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain. 2010;133:1352–67. Pioneering paper demonstrating opposing changes in the default mode network and the salience network in FTLD.PubMedCrossRefPubMedCentral

48.

Farb NA, Grady CL, Strother S, et al. Abnormal network connectivity in frontotemporal dementia: evidence for prefrontal isolation. Cortex. 2013;49:1856–73.PubMedCrossRef

49.

Filippi M, Agosta F, Scola E, et al. Functional network connectivity in the behavioral variant of frontotemporal dementia. Cortex. 2013;49:2389–401.PubMedCrossRef

50.

Whitwell JL, Josephs KA, Avula R, et al. Altered functional connectivity in asymptomatic MAPT subjects: a comparison to bvFTD. Neurology. 2011;77:866–74.PubMedCrossRefPubMedCentral

51.

Day GS, Farb NA, Tang-Wai DF, et al. Salience network resting-state activity: prediction of frontotemporal dementia progression. JAMA Neurol. 2013;70:1249–53.PubMed

52.

Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A. 2004;101:4637–42.PubMedCrossRefPubMedCentral

53.

Sorg C, Riedl V, Muhlau M, et al. Selective changes of resting-state networks in individuals at risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2007;104:18760–5.PubMedCrossRefPubMedCentral

54.

Drzezga A, Becker JA, Van Dijk KR, et al. Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden. Brain. 2011;134:1635–46.PubMedCrossRefPubMedCentral

55.

Dopper EG, Rombouts SA, Jiskoot LC, et al. Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia. Neurology. 2013;80:814–23.PubMedCrossRefPubMedCentral

56.

Borroni B, Alberici A, Cercignani M, et al. Granulin mutation drives brain damage and reorganization from preclinical to symptomatic FTLD. Neurobiol Aging. 2012;33:2506–20.PubMedCrossRef

57.

Agosta F, Sala S, Valsasina P, et al. Brain network connectivity assessed using graph theory in frontotemporal dementia. Neurology. 2013;81:134–43.PubMedCrossRef

58.••

Agosta F, Galantucci S, Valsasina P, et al. Disrupted brain connectome in semantic variant of primary progressive aphasia. Neurobiol Aging. In press. Important work on the abnormalities regarding network connectivity in svPPA.

59.

Guo CC, Gorno-Tempini ML, Gesierich B, et al. Anterior temporal lobe degeneration produces widespread network-driven dysfunction. Brain. 2013;136:2979–91.PubMedCrossRef

60.

Magistretti PJ, Pellerin L. Cellular mechanisms of brain energy metabolism. Relevance to functional brain imaging and to neurodegenerative disorders. Ann N Y Acad Sci. 1996;777:380–7.PubMedCrossRef

61.

Diehl J, Grimmer T, Drzezga A, Riemenschneider M, Forstl H, Kurz A. Cerebral metabolic patterns at early stages of frontotemporal dementia and semantic dementia. PET Stud Neurobiol Aging. 2004;25:1051–6.CrossRef

62.

Diehl-Schmid J, Grimmer T, Drzezga A, et al. Longitudinal changes of cerebral glucose metabolism in semantic dementia. Dement Geriatr Cogn Disord. 2006;22:346–51.PubMedCrossRef

63.

Diehl-Schmid J, Grimmer T, Drzezga A, et al. Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18 F-FDG-PET-study. Neurobiol Aging 2007;28:42-50.

64.

Drzezga A, Grimmer T, Henriksen G, et al. Imaging of amyloid plaques and cerebral glucose metabolism in semantic dementia and Alzheimer's disease. Neuroimage. 2008;39:619–33.PubMedCrossRef

65.

Nestor PJ, Graham NL, Fryer TD, Williams GB, Patterson K, Hodges JR. Progressive non-fluent aphasia is associated with hypometabolism centred on the left anterior insula. Brain. 2003;126:2406–18.PubMedCrossRef

66.

Edwards-Lee T, Miller BL, Benson DF, et al. The temporal variant of frontotemporal dementia. Brain. 1997;120(Pt 6):1027–40.PubMedCrossRef

67.

Jagust WJ, Reed BR, Seab JP, Kramer JH, Budinger TF. Clinical-physiologic correlates of Alzheimer's disease and frontal lobe dementia. Am J Physiol Imaging. 1989;4:89–96.PubMed

68.••

Rabinovici GD, Jagust WJ, Furst AJ, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol. 2008;64:388–401. Very important paper demonstrating the frequent finding of Alzheimer-type amyloid-pathology in lvPPA.PubMedCrossRefPubMedCentral

69.

Drzezga A, Grimmer T, Siebner H, Minoshima S, Schwaiger M, Kurz A. Prominent hypometabolism of the right temporoparietal and frontal cortex in two left-handed patients with primary progressive aphasia. J Neurol. 2002;249:1263–7.PubMedCrossRef

70.

Josephs KA, Duffy JR, Strand EA, et al. Progranulin-associated PiB-negative logopenic primary progressive aphasia. J Neurol. 2014;261:604–14.PubMedCrossRef

71.

Gorno-Tempini ML, Dronkers NF, Rankin KP, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol. 2004;55:335–46.PubMedCrossRefPubMedCentral

72.

Madhavan A, Whitwell JL, Weigand SD, et al. FDG PET and MRI in logopenic primary progressive aphasia versus dementia of the Alzheimer's type. PLoS ONE. 2013;8:e62471.PubMedCrossRefPubMedCentral

73.

Teichmann M, Kas A, Boutet C, et al. Deciphering logopenic primary progressive aphasia: a clinical, imaging and biomarker investigation. Brain. 2013;136:3474–88.PubMedCrossRef

74.••

Matias-Guiu JA, Cabrera-Martin MN, Garcia-Ramos R, et al. Evaluation of the new consensus criteria for the diagnosis of primary progressive aphasia using fluorodeoxyglucose positron emission tomography. Dement Geriatr Cogn Disord. 2014;38:147–52. This work nicely illustrates the value of imaging metabolic abnormalities using FDG-PET for identiying subtypes of PPA.PubMedCrossRef

75.

Villemagne VL, Klunk WE, Mathis CA, et al. Abeta Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 2012;39:209–19.PubMedCrossRefPubMedCentral

76.

Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306–19.PubMedCrossRef

77.

Price JC, Klunk WE, Lopresti BJ, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528–47.PubMedCrossRef

78.

Landau SM, Thomas BA, Thurfjell L, et al. Amyloid PET imaging in Alzheimer's disease: a comparison of three radiotracers. Eur J Nucl Med Mol Imaging 2014;41:1398-407.

79.

Lockhart A, Lamb JR, Osredkar T, et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain. 2007;130:2607–15.PubMedCrossRef

80.

Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol. 2012;11:669–78.PubMedCrossRef

81.

Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA: J Am Med Assoc. 2011;305:275–83.CrossRef

82.

Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131:1630–45.PubMedCrossRefPubMedCentral

83.

Kadir A, Marutle A, Gonzalez D, et al. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh compound B positron emission tomography patient with Alzheimer's disease. Brain. 2011;134:301–17.PubMedCrossRefPubMedCentral

84.

Ye L, Velasco A, Fraser G, et al. In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem. 2008;105:1428–37.PubMedCrossRefPubMedCentral

85.

Bacskai BJ, Hickey GA, Skoch J, et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A. 2003;100:12462–7.PubMedCrossRefPubMedCentral

86.

Rabinovici GD, Furst AJ, O'Neil JP, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68:1205–12.PubMedCrossRef

87.••

Rabinovici GD, Rosen HJ, Alkalay A, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology. 2011;77:2034–42. An important paper, directly comparing the diagnostic strengths of FDG-PET and amyloid-imaging in the differential diagnosis of AD and FTLD.PubMedCrossRefPubMedCentral

88.

Engler H, Santillo AF, Wang SX, et al. In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging. 2008;35:100–6.PubMedCrossRef

89.

Villemagne VL, Ong K, Mulligan RS, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52:1210–7.PubMedCrossRef

90.

Serrano GE, Sabbagh MN, Sue LI, et al. Positive florbetapir PET amyloid imaging in a subject with frequent cortical neuritic plaques and frontotemporal lobar degeneration with TDP43-positive inclusions. J Alzheimers Dis. In press.

91.

Leyton CE, Villemagne VL, Savage S, et al. Subtypes of progressive aphasia: application of the international consensus criteria and validation using beta-amyloid imaging. Brain. 2011;134:3030–43.PubMedCrossRef

92.

Villemagne VL, Okamura N. In vivo tau imaging: obstacles and progress. Alzheim Dement: J Alzheim Assoc. 2014;10:S254–264.CrossRef

93.

Okamura N, Furumoto S, Fodero-Tavoletti MT, et al. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18 F-THK5105 PET. Brain. 2014;137:1762–71.PubMedCrossRef

94.

Harada R, Okamura N, Furumoto S, et al. Comparison of the binding characteristics of [18 F]THK-523 and other amyloid imaging tracers to Alzheimer's disease pathology. Eur J Nucl Med Mol Imaging. 2013;40:125–32.PubMedCrossRef

95.

Fodero-Tavoletti MT, Furumoto S, Taylor L, et al. Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies. Alzheimers Res Ther. 2014;6:11.PubMedCrossRefPubMedCentral

96.

Chien DT, Szardenings AK, Bahri S, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis. 2014;38:171–84.PubMed

97.

Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 2013;34:457–68.PubMed

98.

Okamura N, Furumoto S, Harada R, et al. Novel 18 F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013;54:1420–7.PubMedCrossRef

99.

Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997;18:351–7.PubMedCrossRef

100.

Murray ME, Kouri N, Lin WL, Jack Jr CR, Dickson DW, Vemuri P. Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. Alzheimers Res Ther. 2014;6:1.PubMedCrossRef

101.

Avants BB, Cook PA, Ungar L, Gee JC, Grossman M. Dementia induces correlated reductions in white matter integrity and cortical thickness: a multivariate neuroimaging study with sparse canonical correlation analysis. Neuroimage. 2010;50:1004–16.PubMedCrossRefPubMedCentral

102.

Drzezga A, Barthel H, Minoshima S, Sabri O. Potential clinical applications of PET/MR imaging in neurodegenerative diseases. J Nucl Med 2014.

103.

Agosta F, Canu E, Sarro L, Comi G, Filippi M. Neuroimaging findings in frontotemporal lobar degeneration spectrum of disorders. Cortex. 2012;48:389–413.PubMedCrossRef

Titel: Imaging Frontotemporal Lobar Degeneration
verfasst von: Janine Diehl-Schmid
Oezguer A. Onur
Jens Kuhn
Traugott Gruppe
Alexander Drzezga
Publikationsdatum: 01.10.2014
Verlag: Springer US
Erschienen in: Current Neurology and Neuroscience Reports / Ausgabe 10/2014
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-014-0489-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Bluttest erkennt Parkinson schon zehn Jahre vor der Diagnose

10.05.2024 Parkinson-Krankheit Nachrichten

Ein Bluttest kann abnorm aggregiertes Alpha-Synuclein bei einigen Menschen schon zehn Jahre vor Beginn der motorischen Parkinsonsymptome nachweisen. Mit einem solchen Test lassen sich möglicherweise Prodromalstadien erfassen und die Betroffenen früher behandeln.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2014

Neurologic Manifestations of Gastrointestinal and Liver Diseases

Gut Microbiome and Multiple Sclerosis

The Genetics of Primary Familial Brain Calcifications

X-Linked Adrenoleukodystrophy: Pathogenesis and Treatment

Inflammation and Immune System Activation After Traumatic Brain Injury